# Knight Therapeutics Inc. (GUD.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$10.01, market value C$983 million.

## Valuation
- **P/E (trailing): 66.7×** (5-yr avg 82.8×, 3-yr avg 124.8×). Knight Therapeutics Inc. trades at 66.7× trailing earnings, close to its own five-year average of 82.8×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 38.5×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 1.8×**. Each dollar of revenue is priced at 1.8×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.9×**. Enterprise value is 11.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 11.1%** (5-yr avg -1.6%). Free cash flow equals 11.1% of the market value, above its five-year average of -1.6%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 1.5%**. The inverse of the P/E: 1.5% of the price is earned each year.

## Profitability
- **Gross margin: 39.3%**. Knight Therapeutics Inc. keeps 39.3% of revenue after the direct cost of what it sells.
- **Operating margin: 4.8%**. 4.8% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -1.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -0.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 2.4%**. Return on all capital, debt included, is 2.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.4%**. Each dollar of assets produces 1.4% of profit.

## Growth
- **Revenue growth (1 yr): 21.2%** (3-yr 15.3%/yr, 5-yr 17.7%/yr). Revenue grew 21.2% over the last year, against 17.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -226.2%**. Earnings per share fell 226.2%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 67.1%/yr**. Free cash flow has compounded at 67.1% a year over three years.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Knight Therapeutics Inc. holds more cash than debt.
- **Interest coverage: 2.4×**. Operating profit covers interest 2.4×, thin but manageable.
- **Current ratio: 2.39** (quick 1.57). Current assets cover the next year's liabilities 2.39 times.
- **Altman Z-score: 3.83**. A Z-score of 3.83 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Knight Therapeutics Inc. does not currently pay a dividend, but it returned 1.2% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Knight Therapeutics Inc.; the consensus is strong_buy, with an average price target of C$11.19 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 55.4%** (YTD 65.5%, 3-mo 16.3%). The shares are up 55.4% over twelve months including dividends.
- **From 52-week high: -1.6%** (76.9% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.26** (volatility 26%). Beta of 0.26 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GUD.TO · Page: https://foliofundamentals.com/stocks/gud.to

Not investment advice.